Helius Medical Technologies, Inc. Stock Prediction and Forecast [HSDT]
1 extracted signal · 1 resolved · 0 still active
StockInvest.usIndependent analyst profile- Source published
- 13 Sept 2025, 04:24 UTC
- Recorded by Tahlil Plus
- 18 May 2026, 20:23 UTC
![Video preview for Helius Medical Technologies, Inc. Stock Prediction and Forecast [HSDT]](https://i.ytimg.com/vi/EJEwb1vRY7U/hqdefault.jpg)
AI-generated source summary
The analysis of Helius Medical Technologies (HSDT) on September 12, 2025, indicates a strong buy candidate with a score of 5.767. A gain of 10.36% has been observed since September 10, 2025, resulting in an average return of 3.45% per day. Short-term trends suggest further upward movement. Over the next 3 months, a 39% change is anticipated, expected returns range between -42% and 132%. A 12-month analysis anticipates a change of -37%, potentially putting the future price ranging between 0 and $5.46. The latest trading day showed an increase of 3.14% to $7.56. The stock's volume rose, while exhibiting fluctuation by 23.89% trading between $7.20 and $8.92. There are several buy signals from moving averages are in place and we should consider short term supports from 6.53 and 6.40. MACD analysis also presents a buy signal. A sell signal from a pivot top was triggered 50 days ago. The recommended stop-loss is $7.15.
AI-generated summary based on the source content.
Signal outcomes at a glance
Evaluation CompleteSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
StockInvest.us
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.